Jacobs et al. examined the association between these two through the Cancer Prevention Study II (CPS II), a large group of U. S. adults. In the past, aspirin use had been shown to decrease the risk of colon, stomach, and esophageal cancer in the same group. The group consisted of 1,184,588 people in all, with 508,318 males and 676,270 females who came from all U.S. states as well as the District of Columbia and Puerto Rico (Jacobs et al. 2004, p. 524). In 1982, the group completed a four page questionnaire that gave data regarding “demographics characteristics and various behavioral, environmental, occupational, and dietary factors” (Jacobs et al., 2004, p. 524-525). In 1982, 1984, 1986 and 2000 follow ups were conducted to see if the group members were alive or dead. It was found that 28.1% of them had died and 0.2% could not be traced, whereas 71.7% were alive. A few of the participants had been excluded from the study based on their cancer history, cigarette smoking, or missing data on aspirin use. Resultantly, 987,590 participants were left, out of which 4577 died from pancreatic cancer (Jacobs et al., 2004, p. 525).
Statistics were gathered using the information given by the participants in their 1982 questionnaires, and the Cox model of proportional hazards was used to analyze the ratio of deaths caused by pancreatic cancer, and other potential risk factors, for instance cigarette smoking, dietary habits and family history of pancreatic cancer, were adjusted in the findings (Jacobs et al., 2004, p. 525).
The frequency of aspirin intake was also taken into account, and it was discovered that most of those who took aspirin regularly, i.e. more than 30 times a month, were older and white, just like the majority of participants, who were mostly middle aged or elderly and white (Jacobs et al., 2004, p. 526).
The results showed that there was no relationship between aspirin use and pancreatic cancer mortality. The result was similar